Sarilumab at the ACR 2012 in Washington

Sarilumab, another anti-IL-6 monoclonal antibody, has already been in a phase 2 study in 2011, what’s new? More than presented at the EULAR 2012? http://rheumatologe.blogspot.de/2012/06/sarilumab-news-from-eular-2012.html  

M. C. Genovese and colleagues presented a study on sarilumab in moderate to severe rheumatoid arthritis and looked at improvements of hemoglobin levels (Abstract No. 1320). Conclusion: “Sarilumab treatment for RA over 12 weeks resulted in significant improvements in hemoglobin relative to placebo.” Very good, but do we use biologics to treat haemoglobin levels in our RA patients?

Pavel Belomestnov and colleagues found a substantial reductions in acute phase reactants (Abstract No. 1337). Sarilumab “showed substantial reductions in acute phase reactants relative to placebo.” DAS28, CDAI, SDAI, ACR20-70?

And that’s all! Oops! I’m inclined to give advice to share holders, but I´m a total dummy concerning stock markets. Where are the final results of the phase 2 study? Isn’t there any phase 3 study? OK, lets wait for the 2013 meetings!